Health

STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 19:21:24 UTC.

Briefings

A leaked ESMO conference report revealed early data on a Moderna-Merck melanoma vaccine trial, causing significant disruption to the scheduled presentation. The study involved 1,200 participants with a 6-month follow-up period, showing a 45% reduction in recurrence compared to placebo. Researchers remain uncertain about the long-term safety profile and the clinical significance of the results.

Key points

• A major embargo violation occurred at the ESMO conference, leading to the early release of the most anticipated vaccine trial data.
• The trial included 1,200 participants over a 6-month period with a 45% reduction in recurrence compared to placebo.

Context

The ESMO conference in Madrid was scheduled to begin normally, but the leak of the most anticipated data caused significant disruption to the event's plans.

Limitations

The evidence is limited to a leaked newsletter snippet; the full study details, participant demographics, and statistical significance remain unverified.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 19:32:57 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiabonma53vtejpqiocvxq6dxfsie2h7ihns7bnvwmjdkpbvg22ngu